• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21804 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Necitumumab (lung cancer) - Addendum to Commission A16-17]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Necitumumab - Benefit assessment according to §35a Social Code Book V]
2015     National Evidence-based Healthcare Collaborating Agency (NECA) [NECA Round Table Conference for social consensus]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions: pharmacological treatment for fecal elimination in a person receiving palliative care or presenting a geriatric profile]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions: initiating a blood profile after detecting suggestive symptoms and signs of mild or major neurocognitive disorder]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions: first-line treatment of oral candidiasis in adults]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions: antidiabetics]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions: anticoagulant therapy]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions: acute exacerbation of chronic obstructive pulmonary disease]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions, updated June 2019: palliative care - fever]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions, updated in October 2019: lipid-lowering pharmacologic agents]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions, updated in June 2019: urethral discharge]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions, updated in June 2019: unusual vaginal discharge]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions, updated in June 2019: acute exacerbations of chronic obstructive pulmonary disease (AECOPD)]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions, updated in July 2019: high blood pressure]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions, updated in August 2020: pharmacological treatment of nausea in a person receiving palliative care]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions, updated in August 2020: administration of drugs prescribed via an individual prescription in the event of distress for a person receiving palliative care]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [National expert standards in nursing care]
2021     Norwegian Institute of Public Health (NIPH) [Natalizumab subcutaneous for the treatment of relapsing remitting multiple sclerosis: a rapid health technology assessment - health economic evaluation]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Natalizumab for recurrent-remitting and JC virus seropositive multiple sclerosis]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Narrow band imaging (NBI) in diagnostic gastrointestinal endoscopy]
2010     Andalusian Health Technology Assessment Area (AETSA) [Nanotechnology in medicine]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nalmefene - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Naldemedine (opioid-induced constipation) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Naldemedine (opioid-induced constipation) - Addendum to Commission A20-45]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Nabiximols for spasticity and chronic pain]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Nab-paclitaxel (Abraxane) for the treatment of metastatic pancreatic cancer]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Myopia control spectacle lenses for children and adolescents]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Myomectomy versus no treatment - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2009     Committee for New Health Technology Assessment (CNHTA) [MUTYH gene mutation[Sequencing]]
2013     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Music therapy in palliative setting]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Music therapy in children with developmental disorders]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Music therapy for adolescents with mental and behavioural disorders]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Music therapy - update on the evidence about its indications]
2023     Norwegian Institute of Public Health (NIPH) [Mupirocin nasal ointment as infection prevention prophylaxis prior to orthopaedic prosthesis surgery: a rapid health technology assessment]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Multimodal and interdisciplinary interventions for long term pain]
2010     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Multidisciplinary and multisectoral interventions targeting patients with back pain]
2010     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Multidisciplinary and multisectoral interventions targeting patients with back pain – a health technology assessment]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Multicentre study to analyse the effectiveness of telemedicine in spirometry quality assurance programmes]
2012     The Netherlands Organisation for Health Research and Development (ZonMw) [Multicentered randomized controlled trial to test the cost effectiveness of urodynamics in women with symptoms of stress urinary incontinence in whom surgical treatment is considered]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Multi-stage evaluation and revision of information materials on the mammography screening programme]
2008     Andalusian Health Technology Assessment Area (AETSA) [Multi-slice computerised tomography coronary angiography in detecting coronary stenosis. Meta-analysis and economic report]
2006     Andalusian Health Technology Assessment Area (AETSA) [Multi-slice computerised tomography coronary angiography in detecting coronary stenosis. Meta-analysis and economic report]
2008     Andalusian Health Technology Assessment Area (AETSA) [Multi-slice computerised tomography coronary angiography in detecting coronary stenosis. Meta-analysis and economic report.]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [MSCT coronary angiography in patients with stable and unstable angina: a multicenter study]
2011     Haute Autorite de sante (HAS) [MRI-guided vacuum-assisted breast biopsy (VABB)]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [MRI enterography for the assessment of inflammatory bowel disease]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Motorized Intramedullary nails for bone lenghtening in achondroplasia or hypochondropasia]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Motor-driven continuous passive motion (CPM) devices after interventions on the knee and shoulder joint]
2010     Institute for Clinical Effectiveness and Health Policy (IECS) [Motor rehabilitation using ARMEO]
2009     Committee for New Health Technology Assessment (CNHTA) [Motor cortex stimulation]
2011     Norwegian Knowledge Centre for the Health Services (NOKC) [Motivational interviewing for HIV-related behaviors among men who have sex with men]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Motivational interviewing embedded in planned diabetes care for Type 2 patients: effectiveness and efficiency in general practice especially to improve guideline recommendations on diet and exercise]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mosunetuzumab (follicular lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [More efficient use of corneal donor donations: the Dutch Lamellar Corneal Transplantation Study (DLCTS-Study)]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Montelukast in patients with chronic allergic rhinitis and no asthma]
2013     Andalusian Health Technology Assessment Area (AETSA) [Monoclonal antibodies associated with chemotherapy as first line therapy in metastatic colorectal cancer: relative efficacy, safety and efficiency]
2021     Canary Health Service [Monitoring study: "The sensor glucose monitoring system (flash-type) for type 1 diabetes mellitus in childhood and adolescence]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Monitoring of stable glaucoma patients: evaluation of the effectiveness and efficiency of a glaucoma follow-up unit, staffed by nonphysician health care professionals, as an intermediate step towards glaucoma monitoring in primary care]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Monitoring of exhaled nitric oxide (FENO) to tailor the lowest effective dose of oral corticosteroids in severe asthma (MONOSA-Study)]
2007     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Monitoring depth of anaesthesia - a health technology assessment]
2023     Health Sciences Institute in Aragon (IACS) [Molecular study of common apoE gene polymorphisms associated with familial dysbetalipoproteinaemia and late-onset Alzheimer’s disease]
2011     The Swedish Council on Health Technology Assessment (SBU) [Molecular diagnostic tests for men at higher probability for prostate cancer]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mogamulizumab (mycosis fungoides or Sézary syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2015     Haute Autorite de sante (HAS) [Modification of the nomenclature of procedures in laboratory medicine for research into Treponema pallidum (bacteria responsible for syphilis)]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Models of lower back pain: reliability of a classification model]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Models of collaboration and intervention between primary care and mental health in the care of patients diagnosed with depression: results of a meta-review]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Models for providing care and services to patients who have concurrent mental health and substance use disorders]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Mobile cardiopulmonary exercise test in athletes or cardiopulmonary rehabilitation]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Mistletoe therapy with breast cancer]
2009     Norwegian Knowledge Centre for the Health Services (NOKC) [Misoprostol for induction of labour]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Misoprostol (induction of labour) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Misoprostol (induction of labour) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mirikizumab (ulcerative colitis) - Benefit assessment according to § 35a Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Mirabegron for the treatment of storage dysfunction in patients with neurogenic bladder]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mirabegron - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2003     Basque Office for Health Technology Assessment (OSTEBA) [Minimum characteristics of a cardiac rehabilitation programme in the Basque Autonomous Community]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Miglustat for patients with niemann-pick disease type C]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Miglustat (Zavesca) in the treatment of Niemann-Pick type C disease]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Miglustat (Zavesca) for patients with type 1 gaucher's disease]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Migalastat for Fabry disease]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migalastat (Fabry disease) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migalastat (Fabry disease) – Addendum to Commission A23-88]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migalastat (Fabry disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migalastat - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (acute myeloid leukaemia) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2011     Committee for New Health Technology Assessment (CNHTA) [Microvolt T-wave alternans system]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Microvascular reperfusion after percutaneous coronary intervention for acute anterior myocardial infarction - Assessment according to §137h Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Microvascular reperfusion after percutaneous coronary intervention for acute anterior myocardial infarction - Addendum to commission H20-01]
2012     Andalusian Health Technology Assessment Area (AETSA) [MicroRNAs as a diagnostic tool for lung cancer]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Microperimetry in retinopathies]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Micrometastases and isolated tumour cells: relevant and robust or rubbish? The MIRROR study in breast cancer]
2009     Committee for New Health Technology Assessment (CNHTA) [Microdeletion syndrome screening test(MLPA)]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Microdebrider in nose-throat surgeries]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Microbial collagenase from Clostridium histolyticum - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mexiletine (myotonia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Metreleptin (lipodystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2009     Norwegian Knowledge Centre for the Health Services (NOKC) [Methylnaltrexone for opioid-induced constipation in cancer treatment]